Clinical Trial Update: Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial updating on glycemic control with biphasic insulin aspart 30 in patients with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED